Biological and Medicinal Chemistry

In-Silico FDA-Approved Drug Repurposing to Find the Possible Treatment of Coronavirus Disease-19 (COVID-19)

Authors

Abstract

Identification of potential drug-target interaction for approved drugs serves as the basis of repurposing drugs. Studies have shown polypharmacology as common phenomenon. In-silico approaches help in screening large compound libraries at once which could take years in a laboratory. We screened a library of 1050 FDA-approved drugs against spike glycoprotein of SARS-CoV2 in-silico. Anti-cancer drugs have shown good binding affinity which is much better than hydroxychloroquine and arbidol. We have also introduced a hypothesis named “Bump” hypothesis which and be developed further in field of computational biology.

Version notes

Kindly send all corresponding to: Dr. Shubhangi Dange Associate Professor Department of Microbiology, Government Medical College and Hospital Jalgaon [email protected]

Content

Thumbnail image of In-silico FDA-approved drug repurposing to find the possible treatment of Coronavirus Disease-19 (COVID-19).pdf

Supplementary weblinks